Arcutis Biotherapeutics (ARQT) to Release Quarterly Earnings on Tuesday

Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $60.52 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Arcutis Biotherapeutics Price Performance

ARQT opened at $12.78 on Tuesday. The company has a fifty day moving average price of $13.64 and a two-hundred day moving average price of $11.25. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.38 and a current ratio of 2.46. Arcutis Biotherapeutics has a 52 week low of $6.99 and a 52 week high of $16.20. The firm has a market capitalization of $1.50 billion, a PE ratio of -7.14 and a beta of 1.29.

Insider Activity at Arcutis Biotherapeutics

In related news, insider Patrick Burnett sold 16,023 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $10.14, for a total value of $162,473.22. Following the sale, the insider now directly owns 128,669 shares of the company’s stock, valued at approximately $1,304,703.66. The trade was a 11.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Howard G. Welgus sold 10,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.51, for a total transaction of $125,100.00. Following the completion of the sale, the director now directly owns 161,944 shares in the company, valued at $2,025,919.44. This represents a 5.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,052 shares of company stock valued at $918,490. 9.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ARQT shares. HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price on shares of Arcutis Biotherapeutics in a report on Monday, January 13th. Guggenheim reissued a “buy” rating on shares of Arcutis Biotherapeutics in a research report on Monday, February 10th. Needham & Company LLC reissued a “buy” rating and set a $18.00 price target on shares of Arcutis Biotherapeutics in a research report on Thursday, November 7th. Finally, Mizuho lifted their price target on shares of Arcutis Biotherapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Arcutis Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $16.60.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.